LI-COR now supplies four types of popular secondary antibodies.

Genzyme's BCR-ABL Mutation Analysis test will assist physicians in evaluating resistance to therapy.

The tests identify non-small cell lung cancer patients likely to respond to therapies.

AutovaxID-C reduces the possibility of cross contamination and allows segregation of patient specific vaccine batches.

Octet accelerates antibody development by generating real-time quantitative and kinetics results.

The diagnostic kit will be used to predict whether an individual is at risk of having a heart attack.

PRIDE is designed to exploit the growing mass of information on how the body's complement of proteins is altered in many disease states.